Stock INBP INTEGRATED BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Integrated BioPharma, Inc.

Equities

INBP

US45811V1052

Pharmaceuticals

Market Closed - OTC Markets
Other stock markets
 01:46:54 2024-05-14 pm EDT 		5-day change 1st Jan Change
0.22 USD +1.38% Intraday chart for Integrated BioPharma, Inc. 0.00% -10.28%
May. 10 Integrated BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
Feb. 12 Integrated BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 3.267 6.8 13.3 32.78 14.97 9.92
Enterprise Value (EV) 1 17.4 19.14 23.9 38.51 16.68 11.28
P/E ratio 10.5 x 3.94 x 3.46 x 4.4 x 4.17 x -292 x
Yield - - - - - -
Capitalization / Revenue 0.07 x 0.14 x 0.25 x 0.52 x 0.27 x 0.2 x
EV / Revenue 0.4 x 0.38 x 0.45 x 0.61 x 0.3 x 0.22 x
EV / EBITDA 8.52 x 6.33 x 6.69 x 6.29 x 5.42 x 23.9 x
EV / FCF 24.8 x -150 x 32.3 x 21.6 x 5.05 x 5.92 x
FCF Yield 4.03% -0.67% 3.1% 4.64% 19.8% 16.9%
Price to Book -0.62 x 3.59 x 2.2 x 2.29 x 0.81 x 0.53 x
Nbr of stocks (in thousands) 21,135 29,566 29,566 29,803 29,950 29,950
Reference price 2 0.1546 0.2300 0.4500 1.100 0.4999 0.3312
Announcement Date 9/12/18 8/29/19 9/23/20 9/2/21 9/13/22 9/15/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 43.71 49.98 52.77 63.56 56.25 50.67
EBITDA 1 2.042 3.025 3.571 6.121 3.081 0.471
EBIT 1 1.694 2.704 3.259 5.784 2.745 0.12
Operating Margin 3.88% 5.41% 6.18% 9.1% 4.88% 0.24%
Earnings before Tax (EBT) 1 1.005 2.042 3.088 7.247 2.597 0.1
Net income 1 0.679 1.688 4.108 8.013 3.838 -0.034
Net margin 1.55% 3.38% 7.78% 12.61% 6.82% -0.07%
EPS 2 0.0147 0.0583 0.1300 0.2500 0.1200 -0.001135
Free Cash Flow 1 0.702 -0.1278 0.7408 1.785 3.305 1.906
FCF margin 1.61% -0.26% 1.4% 2.81% 5.88% 3.76%
FCF Conversion (EBITDA) 34.38% - 20.74% 29.16% 107.26% 404.56%
FCF Conversion (Net income) 103.39% - 18.03% 22.28% 86.1% -
Dividend per Share - - - - - -
Announcement Date 9/12/18 8/29/19 9/23/20 9/2/21 9/13/22 9/15/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: Junio 2018 2019 2020 2021 2022 2023
Net Debt 1 14.1 12.3 10.6 5.72 1.71 1.36
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 6.923 x 4.078 x 2.968 x 0.935 x 0.5557 x 2.879 x
Free Cash Flow 1 0.7 -0.13 0.74 1.79 3.3 1.91
ROE (net income / shareholders' equity) -12.2% -101% 103% 78.6% 23.3% -0.18%
ROA (Net income/ Total Assets) 7.11% 9.84% 9.53% 14.9% 6.77% 0.3%
Assets 1 9.544 17.16 43.09 53.62 56.7 -11.49
Book Value Per Share 2 -0.2500 0.0600 0.2000 0.4800 0.6200 0.6300
Cash Flow per Share 2 0.0100 0.0200 0.0100 0.0100 0.0100 0.0400
Capex 1 0.25 0.41 0.21 0.3 0.49 0.12
Capex / Sales 0.57% 0.83% 0.41% 0.46% 0.86% 0.23%
Announcement Date 9/12/18 8/29/19 9/23/20 9/2/21 9/13/22 9/15/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
INTEGRATED BIOPHARMA, INC. Stock Integrated BioPharma, Inc.
-10.28% 6.62M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+37.78% 723B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.47% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.51% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.94% 331B
ABBVIE INC. Stock AbbVie Inc.
+5.14% 288B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.47% 244B
ROCHE HOLDING AG Stock Roche Holding AG
-4.58% 208B
NOVARTIS AG Stock Novartis AG
+10.07% 210B
AMGEN INC. Stock Amgen Inc.
+9.32% 169B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. INBP Stock
  4. Financials Integrated BioPharma, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW